Anksiyete Bozukluklarının Sürdürüm Tedavisi
Özet
Anksiyete bozuklukları, toplumda yaygın olarak görülen, semptomları dalgalanan kronik seyirli psikiyatrik rahatsızlıklardır ve kadınlarda görülme oranı erkeklere kıyasla daha yüksektir. Teşhis ve tedavi süreçlerinde zamanla DSM-5 ve ICD-11 gibi sistemlerde güncellemeler yapılmış; Hamilton Anksiyete Ölçeği gibi araçlar klinik şiddeti belirlemede yaygınlaşmıştır. Tedavi yaklaşımlarında, pozitif fayda ve risk dengeleri göz önünde bulundurularak seçici serotonin geri alım inhibitörleri (SSRI'lar) ve serotonin norepinefrin geri alım inhibitörleri (SNRI'ler) birinci basamak farmakolojik seçenekler olarak önerilmektedir. Panik bozukluğu, yaygın anksiyete bozukluğu ve sosyal anksiyete bozukluğunda bilişsel davranışçı terapiler (BDT) ile farmakoterapi yöntemlerinin bir arada uygulanması, tek başına kullanımlarına kıyasla daha üstün sonuçlar vermektedir. Hızlı etki gösteren benzodiazepinler ise bağımlılık ve tolerans geliştirme riskleri nedeniyle rutin tedavide birinci basamakta tercih edilmeyip, kısa süreli ya da dirençli durumlarda kombinasyon olarak kullanılırlar. Tedavide tam remisyon sağlandıktan sonra nükslerin önlenmesi amacıyla ilaç kullanımına en az 12 ay daha devam edilmesi ve yoksunluk belirtilerini önlemek için dozun kademeli olarak azaltılarak kesilmesi kritik önem taşır. Özel hasta gruplarında; yaşlılarda yan etki duyarlılığı, çocuklarda sertralin-BDT kombinasyonunun etkinliği ve gebelikte ise anne-bebek risk/yarar dengesi titizlikle yönetilmelidir.
Anxiety disorders are common chronic psychiatric conditions with fluctuating symptoms, occurring 1.5 to 2 times more frequently in women than in men. Over time, diagnostic classifications have been updated in manuals like DSM-5, and rating scales such as the Hamilton Anxiety Rating Scale are widely used to monitor severity. In pharmacological management, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are recommended as first-line medications due to their favorable benefit-risk profile. For panic disorder, generalized anxiety disorder, and social anxiety disorder, combining cognitive behavioral therapy (CBT) with pharmacotherapy demonstrates superior efficacy compared to either treatment alone. Although benzodiazepines provide immediate relief, they are not recommended as first-line routines due to risks of dependence and tolerance; instead, they are reserved for short-term or refractory combinations. Following clinical remission, maintenance therapy should be sustained for at least 12 months to prevent relapse, and medications must be tapered gradually to avoid withdrawal reactions. Furthermore, special populations require tailored approaches: older adults exhibit increased sensitivity to adverse effects, children benefit substantially from sertraline combined with CBT, and pharmacotherapy during pregnancy demands a careful evaluation of maternal-fetal risk-benefit ratios.
Referanslar
Kessler RC, Petukhova M, Sampson NA, et al., Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184.
Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655-679.
Chisholm D, Sweeny K, Sheehan P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016;3(5):415-424.
Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-335.
Angst J, Gamma A, Baldwin DS, Ajdacic-Gross V, Rossler W. The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci. 2009;259(1):37-45.
Bandelow B, Baldwin D, Abelli M, et al. Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: neuroimaging and genetics. World J Biol Psychiatry. 2016;17(5):321-365.
Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry. 2017;18(3):162-214.
Moller HJ, Bandelow B, Bauer M, et al. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 1: general aspects and paradigmatic discussion of depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2015;265(1):5-18.
World Health Organization. ICD-11 Beta Draft. World Health Organization; 2017. http://apps.who.int/classifications/icd11/browse/f/en Accessed February 17, 2017.
Bandelow B. Comparison of the DSM-5 and ICD-10: panicand other anxiety disorders. CNS Spectr. 2017:1-3.
Moller HJ, Bandelow B, Volz HP, Barnikol UB, Seifritz E, Kasper S. The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci. 2016;266(8):725-736.
Alonso J, Angermeyer MC, Bernert S, et al. 12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;(420):28-37.
Baldwin DS, Gordon R, Abelli M, et al. The separation of adult separation anxiety disorder. CNS Spectr. 2016;21(4):289-294.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
Bandelow B, Broocks A, Pekrun G, et al. The use of the Panic and Agoraphobia Scale in a controlled clinical trial. Pharmacopsychiatry. 2000;33(5):174-181.
Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-173.
Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The German guidelines for the treatment of anxiety disorders. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):363-373.
Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77-84.
Alonso J, Lepine JP, ESEMeD/MHEDEA 2000 Scientific Committee. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry. 2007;68(suppl 2):3-9.
Smolders M, Laurant M, Verhaak P, et al. Adherence to evidencebased guidelines for depression and anxiety disorders is associated with recording of the diagnosis. Gen Hosp Psychiatry. 2009;31(5):460-469.
Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439.
Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008;9(4):248-312.
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665): 746-758.
Muscatello MR, Spina E, Bandelow B, Baldwin DS. Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol. 2012;27(3):239-253.
Stahl MM, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol. 1997;53(3-4):163-169.
Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24(3):205-214.
Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883-892.
Starcevic V. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother. 2014;14(11):1275-1286.
Stahl SM. Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 2002;63(9):756-757.
Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328:1398-1405.
Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol. 1999;6(2):69-83.
Schweizer E, Rickels K, De Martinis N, Case G, Garcia-Espana F. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med. 1998;28(3):713-720.
Rickels K. Benzodiazepines in the treatment of anxiety. Am J Psychother. 1982;36(3):358-370.
Bandelow B, Lichte T, Rudolf S, et al. The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int. 2014;111(27-28):473-480.
Berney P, Halperin D, Tango R, et al. A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. Psychopharmacol Bull. 2008;41(3):39-47.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M. Canadian clinical practice guidelines for the management of anxiety, post traumatic stress and obsessivecompulsive disorders. BMC Psychiatry 2014, 14 (Suppl 1): S1.
Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, Rapee R, Wilkins G. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust NZJ Psychiatry 2018; 52(12): 1109-72.
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, L!dbetter N, Malizia A, McCrone P, Nabarro D, O'Neill C, Scott J, van derWee N, Wittchen HU. Evidence based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessivecompulsivedisorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014; 28(5): 403-39.
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive of Societies of Biological Psychiatry (WFSBP) guidelines for the Compulsive and Post-Traumatic Stress Disorders. World Federation treatment of anxiety, obsessive-compulsive and pharmacological post-traumatic stress disorders-first revision. World J Biol Psychiatry 2008; 9(4): 248-312.
Van Apeldoorn FJ, Van Hout WJPJ, Timmerman ME, Mersch PA, den Boer JA. Rate of improvement during and across three treatments for panic disorder with or without agoraphobia: cognitive behavioral therapy, selective serotonin reuptake inhibitor or both combined. J Affect Disord 2013; 150(2): 313-9.
Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24(1): 1-14.
Bighelli I, Trespidi C, Castellazzi M, Ciprian! A, Furukawa TA, and benzodiazepines for panic disorder in adults. Cochrane Database Girlanda F, Guaiana G, Koesters M, Barbui C. Antidepressants Syst Rev.
American Psychiatric Association: Practice Guidelines for the Treatment of Patients with Panic Disorder. 2009.
National Institute for Health and Care Excellence (NICE): Generalized anxiety diorder and panic disorder in adults: Management.
Bandelow B, Sagebiel A, Belz M, Görlich Y, Michaelis S, Wedekind D. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-upstudies. Br J Psychiatry 2018; 212(6): 333 8.
Quagliato LA, Cosci F, Shader RI, Silberman EK, Starcevic V, Richard Balon R, Dubovsky SL, Salzman C, Krystal JH, Weintraub SJ, Freire RC, Nardi AE, International Task Force on Benzodiazepines. Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: a meta-analysis of common side effects in acute treatment. J Psychopharmacol 2019; 33(11): 1340-51.
Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebocontrolled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50(11): 884-95.
Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms. J Clin Psychiatry 1988; 49(8): 293-301.
Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, LiuDumaw M. Pregabalin in generalized anxiety disorder: a placebocontrolled trial. Am J Psychiatry 2003;160(3): 533-40.
Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety diorder: updated systematic review and meta-analysis. Int Clin Psychopharmacol 2017; 32(1): 49
Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-192.
Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64(3):250-258.
Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005;66(10):1270-1278.
Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002;59(12):1111-1118.
Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18(9):673-681.
Katzman MA, Brawman-Mintzer O, Reyes EB, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11-24.
Yoshinaga N, Matsuki S, Niitsu T, et al. Cognitive behavioral therapy for patients with social anxiety disorder who remain symptomatic following antidepressant treatment: a randomized, assessor-blinded, controlled trial. Psychother Psychosom. 2016;85(4):208-217.
Hall J, Kellett S, Berrios R, et al. Efficacy of cognitive behavioral therapy for generalized anxiety disorder in older adults: systematic review, meta-analysis, and meta-regression. Am J Geriatr Psychiatry. 2016;24(11):1063-1073.
Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753-2766.
Committee on Safety of Medicines (2014). Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs): use and safety. Medicines & Healthcare products Regulatory Agency (MHRA).
Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397-2407.
Oyebode F, Rastogi A, Berrisford G, et al. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther. 2012;135(1):71- 77.
Muzik M, Hamilton SE. Use of antidepressants during pregnancy? What to consider when weighing treatment with antidepressants against untreated depression. Matern Child Health J. 2016;20(11):2268-2279.
